Devising a Polyoxometalate-Based Functional Material as an Efficient Electrocatalyst for the Hydrogen Evolution Reaction.

Hydrogen is the solution to all the problems associated with the energy crisis. Generating hydrogen from water splitting is one of the greener approaches, but it requires an efficient catalyst that is economical for the bulk production of hydrogen. The transition metal-aqua coordination complexes, which are otherwise inactive/unstable for electrochemical hydrogen evolution reaction (HER) activity, can efficiently be utilized for the same by attaching these metal-aqua species on a stable support. With a similar approach, we have synthesized and structurally characterized a two-dimensional polyoxometalate (POM)-copper complex hybrid that supports a copper(II)-aqua-bypyridine complex with a molecular formula of the overall system, [{CuII(2,2'-bpy)(H2O)2}][{CoIIWVI12O40}{CuII(2,2'-bpy)(H2O)}{CuII(2,2'-bpy)}]·2H2O (1). The bis(aqua)-mono(bipyridine) Cu(II)-complex fragment {CuII(2,2'-bpy)(H2O)2}2+, attached to the two-dimensional POM-Cu-complex support, acts as an active catalytic center that catalyzes the electrochemical HER. The electrochemical studies done for this work enabled us to understand the role of compound 1 as an electrocatalyst for the HER in near-neutral medium (pH 4.8), under buffered conditions (acetate buffer). Through detailed electrochemical experiments including controlled ones, we understand that compound 1 follows a proton-coupled electron transfer (PCET) pathway with one proton and one electron involvement in the HER. The overpotential required to achieve a current density of 1 mA/cm2 is found to be 520 mV with a Faradaic efficiency of 81%.

Neem leaf glycoprotein partially rectifies suppressed dendritic cell functions and associated T cell efficacy in patients with stage IIIB cervical cancer.

Myeloid-derived dendritic cells (DCs) generated from monocytes obtained from stage IIIB cervical cancer (CaCx IIIB) patients show dysfunctional maturation; thus, antitumor T cell functions are dysregulated. In an objective to optimize these dysregulated immune functions, the present study is focused on the ability of neem leaf glycoprotein (NLGP), a nontoxic preparation of the neem leaf, to induce optimum maturation of dendritic cells from CaCx IIIB patients. In vitro NLGP treatment of immature DCs (iDCs) obtained from CaCx IIIB patients results in upregulated expression of various cell surface markers (CD40, CD83, CD80, CD86, and HLA-ABC), which indicates DC maturation. Consequently, NLGP-matured DCs displayed balanced cytokine secretions, with type 1 bias and noteworthy functional properties. These DCs displayed substantial T cell allostimulatory capacity and promoted the generation of cytotoxic T lymphocytes (CTLs). Although NLGP-matured DCs derived from CaCx monocytes are generally subdued compared to those with a healthy monocyte origin, considerable revival of the suppressed DC-based immune functions is noted in vitro at a fairly advanced stage of CaCx, and thus, further exploration of ex vivo and in vivo DC-based vaccines is proposed. Moreover, the DC maturating efficacy of NLGP might be much more effective in the earlier stages of CaCx, where the extent of immune dysregulation is less and, thus, the scope of further investigation may be explored.

Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer.

Despite being a pleiotropic cytokine, the therapeutic potential of interferon α2b (IFNα2b) is debatable. Thus, the need for identifying predictive marker(s) for patients who are most likely to benefit from the treatment is pivotal for avoiding the exposure of nonresponsive patients to the toxicity of the treatment. To account for the attenuated efficacy of the drug, we have verified its dendritic cell (DC) maturating ability from monocytes of cervical cancer stage IIIB (CaCx-IIIB) patients. First, we evaluated the status of monocytes from CaCx-IIIB and healthy women by conducting flow cytometric studies of various activation markers and a cytokine analysis by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Immature DCs were then generated from these monocytes and matured with low-dose IFNα2b (1500 units/mL). A functional and phenotypic comparative analysis of these matured DCs was performed by flow cytometric, proliferative, cytotoxic, and enzyme-linked immunosorbent assays. Our study shows that monocytes isolated from CaCx-IIIB are impaired, and in vitro maturation with IFNα2b did not significantly improve the functional repertoire of DCs generated from these monocytes in comparison with healthy controls. This impairment of monocytes might be a plausible reason for the attenuated efficacy of this drug alone in treating CaCx-IIIB patients, and this imbalance of immune parameters associated with the stage of malignancy might be considered an effective marker to design a proper therapeutic regimen.